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Introduction: Familial hypercholesterolemia (FH) is an inherited disorder characterized by ele-
vated plasma levels of low-density lipoprotein cholesterol (LDL-C) associated with premature
cardiovascular disease.
Methods: Using the data from the START (STable Coronary Artery Diseases RegisTry) study, a
nationwide, prospective survey on patients with stable coronary artery disease (CAD), we
described prevalence and lipid lowering strategies commonly employed in these patients. The
study population was divided into “definite/probable FH,” defined as a Dutch Lipid Clinic Net-
work (DLCN) score ≥6, “possible FH” with DLCN 3-5, and “unlikely FH” in presence of a
DLCN <3.
Results: Among the 4030 patients with the DLCN score available, 132 (3.3%) were classified as
FH (2.3% with definite/probable and 1.0% with possible FH) and 3898 (96.7%) had unlikely
FH. Patients with both definite/probable and possible FH were younger compared to patients
not presenting FH. Mean on-treatment LDL-C levels were 107.8  41.5, 84.4  40.9, and
85.8  32.3 (P < 0.0001) and a target of ≤70 mg/dL was reached in 10.9%, 30.0%, and 22.0%
(P < 0.0001) of patents with definite/probable, possible FH, and unlikely FH, respectively. Statin
therapy was prescribed in 85 (92.4%) patients with definite/probable FH, in 38 (95.0%) with
possible FH, and in 3621 (92.9%) with unlikely FH (P = 0.86). The association of statin and ezeti-
mibe, in absence of other lipid-lowering therapy, was more frequently used in patients with defi-
nite/probable FH compared to patients without FH (31.5% vs 17.5% vs 9.5%; P < 0.0001).
Conclusions: In this large cohort of consecutive patients with stable CAD, FH was highly preva-
lent and generally undertreated with lipid lowering therapies.
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1 | INTRODUCTION
Familial hypercholesterolemia (FH) is a common monogenic disorder
mainly caused by mutations in the low-density lipoprotein (LDL)
receptor inherited in a codominant fashion.1 FH may also results from
defects in two other major genes, apolipoprotein B and proprotein
convertase subtilisin/kexin 9 (PCSK-9), which influence plasma LDL
clearance by affecting the efficiency of ligand-receptor interaction.1
The inadequate LDL clearance manifested in all FH genotypes leads
to marked elevations of plasma LDL-cholesterol (LDL-C) levels, thus*See Appendix for a complete list of centers and investigators.
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causing accelerated atherosclerosis and premature cardiovascular
(CV) disease.1 Indeed, it has been clearly demonstrated that FH sub-
stantially increase the risk of recurrence of CV events in patients with
established coronary artery disease (CAD).2
Despite the wealth of knowledge on this disorder, FH remains
underdetected and undertreated in most countries.1,3–8 In particular,
the diagnosis of FH in patients with CAD is even less recognized, so
that a key opportunity for detecting FH has not been embedded in
the routine clinical care. Using the data from the STable Coronary
Artery Diseases RegisTry (START) study,9 a nationwide registry on
patients with stable CAD presenting to cardiologists, we sought to
describe the prevalence of FH and the use of lipid lowering therapies
in these high-risk patients.
2 | METHODS
The design and main results of the START registry have been pub-
lished elsewhere.9 Briefly, the START was a prospective, observa-
tional, nationwide study aimed to evaluate the current presentation,
management, treatment, and quality of life of stable CAD patients as
seen by cardiologists in clinical practice in Italy, during a 3-month
period.9 Enrolment was made at the end of outpatient or day-hospital
visit or at hospital discharge.
The Italian Association of Hospital Cardiologists (ANMCO) invited
to participate all Italian cardiology wards, including university teaching
hospitals, general and regional hospitals, and private clinics following
stable CAD patients. No specific protocols or recommendations for
evaluation, management, and/or treatment have been put forth during
this observational study. However, current guidelines for the manage-
ment of patients with stable CAD have been discussed during the
investigator meetings.
All patients were informed of the nature and aims of the study
and asked to sign an informed consent for the anonymous manage-
ment of their individual data. Local Institutional Review Boards (IRB)
approved the study protocol according to the current Italian rules.
One-hundred eighty-three cardiology centers included consecu-
tive patients in the survey in different periods of 3 months between
March 2016 and February 2017.9
2.1 | Diagnosis of familial hypercholesterolaemia
We assessed the presence of FH based on age, personal and family
history of premature atherosclerosis, and LDL-C levels. We used the
validated Dutch Lipid Clinic Network (DLCN) algorithm; it is a scoring
system based on clinical factors endorsed by many guidelines world-
wide, including the European Society of Cardiology and the European
Atherosclerosis Society.10–13
A definite/probable diagnosis of FH was considered when the
DLCN score was 6 or higher, and a possible FH when the score was
3 to 5.14 Patients with a DLCN score <3 were classified as “no/
unlikely” FH.14
To estimate the pretreatment LDL-C level, we multiplied the on-
treatment LDL-C level by a correction factor based on the potency of
their treatment regimen as described in detail before.15 In brief, we
determined the estimated LDL-C lowering potency of a specific lipid-
lowering drug and dose. We multiplied the on-treatment LDL-C level
with that treatment potency, yielding an estimated pretreatment LDL-
C level. In case of concomitant use of ezetimibe, we increased the rel-
ative LDL-C reduction by 15%, based on a previously reported
estimation.16
2.2 | Statistical analysis
The study cohort was stratified according to FH: definite/probable
FH; possible FH and unlikely FH. Categorical variables are presented
as number and percentages and compared by the χ2 test. Continuous
variables are presented as mean and SD, except for triglycerides levels
and dosage of statins, which are reported as median and interquartile
range (IQR). Continuous variables were compared by the t test, if nor-
mally distributed, or by the Mann-Whitney U test, if not. Multiple
comparisons between FH groups (unlikely FH vs possible FH; possible
FH vs definite/probable FH; definite/probable FH vs unlikely FH)
were performed, considering the Bonferroni correction. A P-value
<0.05 was considered statistically significant. All tests were two-sided.
Analyses were performed with SAS system software, version 9.4: SAS
Institute Inc., Cary, NC, USA.
3 | RESULTS
Among the 5070 consecutive stable CAD patients enrolled, 1040
(20.5%) were not classified with the DLCN score due to data missing
and therefore excluded from the analysis. These patients presented
more frequently high-risk features such as hypertension, peripheral
artery disease, history of atrial fibrillation or heart failure, and prior
stroke/transient ischemic attack (TIA) compared to patients in whom
the DLCN score was assessed (Table S1, Supporting Information).
Among the remaining 4030 patients with the DLCN score
assessed, 132 (3.3%) were classified as FH (2.3% with definite/proba-
ble and 1.0% with possible FH) and 3898 (96.7%) had no/unlikely FH.
Baseline characteristics of patients with definite/probable, possi-
ble FH and without FH are shown in Table 1. Those with both defi-
nite/probable and possible FH were younger compared to patients
not presenting FH. In addition, patients with definite/probable FH
presented higher levels of total cholesterol compared to patients with
possible FH and unlikely FH, at the time of enrolment (Table 1). Nota-
bly, among patients with data available, mean LDL-C levels were
107.8  41.5, 84.4  40.9, and 85.8  32.3 (P < 0.0001) and a target
of ≤70 mg/dL was reached in 10.9%, 30.0%, and 22.0% (P < 0.0001)
of patents with definite/probable, possible FH and unlikely FH,
respectively. After adjustment for different statins and dosages, mean
LDL-C values resulted as 217.9  97.0, 172.2  88.8, and
162.3  71.9 (P < 0.0001) for patents with definite/probable, possi-
ble FH and unlikely FH, respectively.
The number of coronary vessels with significant stenoses among
the 110 (83.3%) patients with FH (76 with definite/probable and
34 with possible FH) and the 3380 (86.7%) without FH who under-
went coronary angiography was not statistically different (Figure S1).
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3.1 | Lipid-lowering drugs and lifestyle
recommendations
At the time of discharge or at the end of the visit, a statin was pre-
scribed in 85 (92.4%) patients with definite/probable FH, in
38 (95.0%) with possible FH, and 3621 (92.9%) without FH (P = 0.86).
A low dose of statin (atorvastatin ≤10 mg/d, fluvastatin ≤40 mg/d,
lovastatin ≤20 mg/d, pravastatin ≤20 mg/d, rosuvastatin ≤5 mg/d, or
simvastatin ≤20 mg/d) was prescribed in 518 (12.9%) patients (16.3%
with definite/probable, 17.5% with possible FH, and 12.7% without
FH; P = 0.72). The main reasons for the lack of statins prescription or
for their low dose prescription in 804 patients are depicted in
Figure 1.
Atorvastatin was the mainly employed statin compound, espe-
cially among patients without FH or with possible FH, while rosuvas-
tatin were prescribed more frequently in patients with FH, especially
among those with definite/probable FH (Figure 2). The mean dosages
of statins prescribed did not differ between the three groups
(Table 2). Concerning the other lipid-lowering agents, ezetimibe alone
was used in 2.2% of patients with definite/probable FH, none of pos-
sible FH patients, and 1.3% of those without FH (P = 0.58), while
omega-3 fatty acids alone and fibrates alone were prescribed in
patients without FH only (0.5% and 0.1% of cases, respectively).
The association of statin and ezetimibe in the absence of other
lipid-lowering therapy was more frequently used in patients with
TABLE 1 Baseline clinical characteristics, hemodynamic and laboratory variables of patients with and without FH
No FH
n = 3898
FH possible
n = 40
FH definite/probable
n = 92 P value
Age (years), mean  SD 68  11e 61  10 61  10g <0.0001
Age >75 years, n (%) 1028 (26.4)e 2 (5.0) 7 (7.6)g <0.0001
Females, n (%) 765 (19.6) 8 (20.0) 15 (16.3) 0.73
BMI (kg/m2), mean  SD 27.3  4.0 28.0  5.4 26.6  4.2 0.14
Active smokers, n (%) 677 (17.4) 9 (22.5) 17 (18.5) 0.67
Diabetes mellitus, n (%) 1186 (30.4) 12 (30.0) 22 (23.9) 0.41
Hypertension,a n (%) 3056 (78.4) 32 (80.0) 69 (75.0) 0.71
History of atrial fibrillation, n (%) 515 (13.2) 2 (5.0) 12 (13.0) 0.31
Chronic renal dysfunction,b n (%) 477 (12.2) 2 (5.0) 9 (9.8) 0.30
Peripheral artery disease,c n (%) 329 (8.4) 3 (7.5) 9 (9.8) 0.88
COPD, n (%) 423 (10.9) 3 (7.5) 7 (7.6) 0.49
Malignancy, n (%) 256 (6.6) 3 (7.5) 3 (3.3) 0.43
Depression, n (%) 404 (10.4) 4 (10.0) 6 (6.5) 0.49
Previous stroke/TIA, n (%) 200 (5.1) 2 (5.0) 4 (4.4) 0.94
History of major bleeding events,d n (%) 74 (1.9) 1 (2.5) 0 (0.0) 0.39
History of heart failure, n (%) 507 (13.0) 3 (7.5) 9 (9.8) 0.39
Prior ACS, n (%) 2643 (67.8) 31 (77.5) 65 (70.7) 0.36
Previous revascularization, n (%) 3019 (77.5) 35 (87.5) 79 (85.9) 0.05
Ejection fraction (%), mean  SD (available for 3657 [90.7%]
pts)
54  9 55  10 56  11 0.06
SBP (mm Hg), mean  SD 130  17 126  17 129  15 0.30
HR (bpm), mean  SD 66  11 66  10 65  9 0.94
Hb (g/dL), mean  SD (available for 3252 [80.7%] pts) 13.6  1.7 14.0  2.0 13.9  1.5 0.09
Creatinine (mg/dL), mean  SD (available for 3252 [80.7%]
pts)
1.1  0.6 1.0  0.2 1.0  0.3 0.12
Total cholesterol (mg/dL), mean  SD (available for 2889
[71.7%] pts)
153.6  37.8 157.4  44.8f 177.1  43.6g <0.0001
Triglycerides (mg/dL), median (IQR) (available for 2800
[69.5%] pts)
111 [83-151] 130 [117-149] 125 [82-161] 0.07
Glycemia (mg/dL), mean  SD (available for 2971 [73.7%]
pts)
113.6  35.9 124.6  41.9f 101.5  23.8g 0.0009
Abbreviations: ACS, acute coronary syndrome (STEMI or NSTE-ACS) occurred at least 30 days from enrolment; BMI, body mass index; COPD, chronic
obstructive pulmonary disease; FH, familiar hypercholesterolemia; Hb, hemoglobin; HR, heart rate; IQR, interquartile range; SBP, systolic blood pressure;
TIA, transient ischemic attack.
a Systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or use of blood pressure lowering drugs.
b Dialysis, history of renal transplant or creatinine levels >1.5 mg/dL.
c History of claudication; amputation for arterial insufficiency; aorta-iliac occlusive disease reconstruction surgery; peripheral vascular bypass surgery,
angioplasty, or stent; documented abdominal aortic aneurysm, aneurysm repair or stent; and documented positive noninvasive testing such as abnormal
ankle-brachial index or pulse volume recording.
d Fatal bleeding, or clinically evident bleeding with hemoglobin reduction ≥2 g/dL or requiring transfusion or hospitalization.
e P < 0.017 for comparison between possible FH and No FH patients (by Bonferroni correction).
f P < 0.017 for comparison between possible FH and definite/probable FH patients (by Bonferroni correction).
g P < 0.017 for comparison between definite/probable FH and No FH patients (by Bonferroni correction).
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definite/probable FH compared to other groups, while omega-3
fatty acids in association with statins or ezetimibe were frequently
employed in patients with possible FH (Figure 3). As a whole, high-
intensity lipid-lowering medications (atorvastatin 40-80 mg or
rosuvastatin 20-40 mg or simvastatin/ezetimibe combination) were
used in 59 (64.1%) with definite/probable FH, 22 (55.0%) with
possible FH, and 2327 (59.7%) patients with unlikely
FH (P = 0.43).
Finally, a personalized diet was prescribed in 79.4%, 85.0%, and
56.8% (P < 0.0001) and physical activity programs were suggested in
83.7%, 75.0%, vs 64.2% (P = 0.0002), of patients with definite/proba-
ble FH, possible FH, and unlikely FH, respectively.
4 | DISCUSSION
In this large cohort study of patients with stable CAD, the prevalence
of definite/probable FH was 2.3% and, including possible FH, the rate
reached 3.3%, a number approximately 8 to 10 times higher than esti-
mates made in the general population using similar diagnosis algo-
rithms.3–8,15,16 The prevalence of FH has been also investigated in an
unselected population of patients with acute coronary syndromes6 or
in cohort of patients with early-onset manifestation of coronary ische-
mic events,7,8 thus not providing a reliable representation of FH fre-
quency in the real word patients with stable CAD. To the best of our
knowledge, this is the first study assessing the prevalence of FH in
FIGURE 1 Patients with definite/probable, possible FH and without FH not receiving or receiving low dose statins (Atorvastatin ≤10 mg/d,
Fluvastatin ≤40 mg/d, Lovastatin ≤20 mg/d, Pravastatin ≤20 mg/d, Rosuvastatin ≤5 mg/d, Simvastatin ≤20 mg/d) at the time of discharge/end of
the visit (left panel). Reasons for lack of statins or low dose statins prescription (right panel)
FIGURE 2 Statin compounds prescribed at the time of discharge/end of the visit in patients with definite/probable, possible FH and without
FH. &P < 0.017 for comparison between definite/probable FH and unlikely FH
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patients with stable CAD. In our study, patients with FH were younger
and presented a higher prevalence of previous revascularization pro-
cedures compared to patients without FH. This finding is in accor-
dance with the known finding that premature CAD is an established
phenomenon of FH, with the average mean age of onset of coronary
symptoms shown to be 45 years in men and 55 years in women.17 In
this regard, there are several evidences suggesting that the extent of
atherosclerosis is likely to be higher in patients with FH, especially in
those with definite FH, compared to other patients. This finding is
most likely to be due to the fact that subjects with definite FH have
had severely elevated LDL-C level since birth, and thus, have a greater
cumulative “LDL-C burden”.10
The standardized mortality rate of CAD and risk of a coronary
event are increased in people with untreated FH.2,12 The specific evi-
dence for treating hypercholesterolemia in FH is based on selected
observational studies showing that long-term statin medication
decreases CAD events and mortality in FH to a level comparable to or
approaching that of the reference population. In addition, primary pre-
vention with statin treatment in FH is more effective in terms of abso-
lute number of prevented deaths than interventions in the setting of
secondary prevention.18 Therefore, high-intensity statins and combi-
nation therapy with ezetimibe are the mainstay of treatment that
should be started as early as the diagnosis of FH is made.1 Consis-
tently with previous reports4,6 our data indicated that CAD patients
with FH, despite statin use comparable with that observed in non-FH,
attained 2 to 3 times less frequently LDL-C targets. This phenomenon
was mainly remarkable in CAD patients with definite/ probable FH, as
the vast majority (approximately 90%) of them presented LDL-C levels
above 70 mg/dL. This may be due to the low rate of prescription of
high-intensity statin alone or in association with ezetimibe. In our
cohort, a high intensity statin regimen was used in approximately 60%
of definite/probable FH patients and an association of statin with eze-
timibe was employed in only 32% of them. We have identified that no
prescription or low dose statin prescription in FH patients was mainly
TABLE 2 Dosages of statins prescribed at the end of the visit/discharge in patients with or without FH
No FH
n = 3898
FH possible
n = 40
FH definite/probable
n = 92 P value
Atorvastatin (mg/d), mean  SD
Median [IQR]
41.7  20.9
40 [20-40]
44.2  21.9
40 [40-40]
40.6  20.1
40 [20-40]
0.80
Simvastatin (mg/d), mean  SD
Median [IQR]
25.9  11.6
20 [20-40]
20.0  0.0
20 [20-20]
27.9  16.9
20 [20-40]
0.70
Rosuvastatin (mg/d), mean  SD
Median [IQR]
14.1  7.0
10 [10-20]
15.0  11.6
10 [7.5-20]
16.9  7.9
20 [10-20]
0.28
Pravastatin (mg/d), mean  SD
Median [IQR]
31.5  11.1
40 [20-40]
— 40a 0.47
Lovastatin (mg/d), mean  SD
Median [IQR]
30.7  10.3
40 [20-40]
— — —
Fluvastatin (mg/d), mean  SD
Median [IQR]
62.5  35.0
80 [45-80]
— — —
Abbreviations: FH, familiar hypercholesterolemia; IQR, interquartile range.
a Only one patient treated with pravastatin.
FIGURE 3 Associations of lipid lowering strategies in patients with definite/probable, possible FH and without FH (other possible combinations
not shown were used in <0.5% of cases). &P < 0.017 for comparison between definite/probable FH and unlikely FH. *P < 0.017 for comparison
between possible FH and unlikely FH
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due to medical decision or because the drugs were not tolerated by
the patient. These findings underline the fact that we still need educa-
tion and implementation of guidelines recommendations in this set-
ting, as cardiologists seem to underscore the importance of FH
recognition in patients at already high/very high risk due to clinically
manifest CAD.
Nevertheless, our data further underlying the difficulties in the
treatment of FH CAD patients with standard medications. The
recently available monoclonal antibodies inhibiting the PCSK-9 have
been reported to be particularly promising in the treatment of FH
patients requiring additional lipid-lowering.19–22
In addition, recent large clinical trials have demonstrated the ben-
efit of these agents on top of high intensive statin therapy in reducing
adverse CV outcomes among patients with CV disease.23–25 In our
cohort, patients eligible to PCSK-9 inhibitors according to recent
European Society of Cardiology/European Atherosclerosis Society
(ESC/EAS) recommendations,26 were 9% of those with LDL-C values
available. It is worth to mention that the PCSK-9 inhibitors become
available in Italy from March 2017, immediately after the conclusion
of the START registry. In addition, in Italy the criteria for the reim-
bursement of these medication are based on different criteria, as only
CAD patients taking high potency statins (atorvastatin >40 mg/d and
over or rosuvastatin >20 mg/d) in association with ezetimibe must be
considered eligible for these therapies. Therefore, our estimate cannot
representative of clinical setting in Italy.
4.1 | Study limitations
Our study must be evaluated in the light of some limitations. First, we
were not able to assess the prevalence of FH using the DLCN score in
around 20% of patients included in the survey, therefore the actual
incidence of FH could be underestimated. In addition, DLCN score
was assessed by researchers and not all clinical criteria of diagnosis
algorithms, such as Achilles xanthoma or LDL-C in family members,
have been evaluated. This is a limitation of previous studies about FH
prevalence8,10,16,23 and this would likely underestimate the true prev-
alence of FH. Another reason for a possible underestimation of FH in
our series is that lipid profiles were missing in around 30% of enrolled
patients, especially in those with unlikely FH (Table S2). Second, we
used a phenotypic diagnosis of FH that may not accurately identify
monogenic FH27,28 . However, in a recent study29 that confirmed
genetically the diagnosis of FH in patients with acute coronary syn-
dromes, about 1/3 were classified as polygenic, thus suggesting that
only a minority of CAD patients may show a nonmonogenic form of
FH. Third, the data reported in the present analysis are limited to the
time of the visit or hospitalization period and we do not have data on
long-term persistence to prescribed therapies, their changes and rela-
tive outcomes. However, a clinical follow-up at 1 year from enrolment
is ongoing. Finally, even if the participating centers were asked to
include in the registry all consecutive patients admitted with stable
CAD, we were not able to verify the enrolment process, due to the
absence of administrative auditing. We believe that it is unlikely, how-
ever, that selective enrolment in few sites may have substantially
changed the study results.
5 | CONCLUSIONS
In a large cohort of consecutive patients with stable CAD managed by
cardiologists, we found a high prevalence of FH. Only a minority of
patients with FH received recommended doses or associations of lipid
lowering therapies, advocating for better identification of this disorder
and specific organization pathways for these high-risk patients.
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